Tango Therapeutics Inc - SIC # 8731 - COMMERCIAL PHY_SICAL AND BIOLOGICAL RESEARCH

Ticker Exchange SIC # Website Latest Ticker
TNGX Nasdaq 8731 https://www.tangotx.com/

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Tango Therapeutics Inc

Tango Therapeutics to Participate in Upcoming Investor Conferences - Jun 1st, 2023 11:00 am
Tango Therapeutics Reports First Quarter 2023 Financial Results and Provides Business Highlights - May 9th, 2023 11:00 am
Tango Therapeutics Presents Preclinical Data on Precision Oncology Programs at the American Association of Cancer Research 2023 Annual Meeting - Apr 18th, 2023 8:30 pm
Tango Therapeutics Announces FDA Clearance of Investigational New Drug Application for TNG260, a First-in-Class CoREST Inhibitor for the Treatment of STK11-Mutant Cancers - Apr 3rd, 2023 11:00 am
Tango Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Highlights - Mar 27th, 2023 11:00 am
Tango Therapeutics to Highlight Preclinical Data on Precision Oncology Programs at the American Association of Cancer Research 2023 Annual Meeting - Mar 15th, 2023 12:11 am
Tango Therapeutics Announces Limited Exposure to Silicon Valley Bank - Mar 11th, 2023 3:15 am
Tango Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Mar 6th, 2023 12:00 pm
Tango Therapeutics Announces Appointment of Adam Crystal, M.D., Ph.D. as President of Research and Development - Feb 28th, 2023 12:00 pm
Tango Therapeutics Announces FDA Clearance of Investigational New Drug Application for TNG462; Provides Additional Business Updates - Jan 25th, 2023 12:00 pm
HOOKIPA Pharma Appoints Katia Schlienger, M.D., Ph.D., Chief Medical Officer and Malte Peters, M.D., to Board of Directors - Dec 15th, 2022 12:00 pm
Tango Therapeutics Reports Third Quarter 2022 Financial Results and Provides Business Highlights - Nov 10th, 2022 12:00 pm
Tango Therapeutics Announces Presentation of Preclinical Data on PRMT5 Inhibitors TNG908 and TNG462 in Three Abstracts Accepted at 34th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics - Oct 19th, 2022 11:00 am
Tango Therapeutics Announces Presentation of Preclinical Data on TNG260 and Discovery Platform Advances at SITC 37th Annual Meeting - Oct 5th, 2022 12:10 pm
Tango Therapeutics to Participate in the H.C. Wainwright 24th Annual Global Investment Conference - Sep 6th, 2022 11:00 am
The Tango Therapeutics, Inc. (NASDAQ:TNGX) Second-Quarter Results Are Out And Analysts Have Published New Forecasts - Aug 13th, 2022 12:27 pm
Tango Therapeutics Reports Second Quarter 2022 Financial Results and Provides Business Highlights - Aug 10th, 2022 11:00 am
Tango Therapeutics to Participate in the 13th Annual Wedbush PacGrow Healthcare Conference - Aug 2nd, 2022 11:00 am
Tango Therapeutics Added to Russell 2000®, 3000® and Microcap® Indexes - Jun 27th, 2022 11:00 am
We Think Tango Therapeutics (NASDAQ:TNGX) Can Afford To Drive Business Growth - Jun 20th, 2022 11:26 am